Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Attention Deficit Hyperactivity Disorder
Clinical Trial
NCT00922636Last updated: 12/5/2025
LLY
Eli Lilly and Company
